Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026

October 23, 2026 To, To, National Stock Exchange of India Limited, BSE Limited, “Exchange Plaza”, Corporate Relationship Department, 5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring, Bandra- Kurla Complex Bandra (East), P.J. Towers, Dalal Street, Mumbai – 400 051 Mumbai – 400 001 NSE Symbol: GLENMARK BSE Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 61/26-27 Our Reference No. 61/26-27 Dear Sir/ Madam, Sub: Intimation under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”) - Board Meeting to consider and approve the Unaudited Financial Results of Glenmark Pharmaceuticals Limited (“the Company”) for the quarter and half year ended September 30, 2026. This is to inform you that a meeting of the Board of Directors of the Company will be held on Thursday, November 5, 2026, inter alia, to consider and approve the Unaudited Financial Results (both Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026. Please note that the notice of the aforesaid meeting is also being made available on the website of the Company in terms of Regulation 46(2) of the SEBI LODR. Further, the Unaudited Financial Results of the Company shall be submitted to the Stock Exchanges after the conclusion of the aforesaid Board Meeting on Thursday, November 5, 2026, and will also be hosted on the website of the Company on the said date and thereafter shall be published in the newspapers, in accordance with the SEBI LODR. Pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, and Company’s Code of Conduct for Prevention of Insider Trading, the Company has already informed the Stock Exchanges vide its letter dated September 28, 2026 that the window for trading in securities of the Company for the Designated Persons viz, Directors, Key Managerial Personnel, Identified Employees / Persons of the Company including the Immediate Relatives of the Designated Persons and the Connected Persons, etc. would remain closed from October 01, 2026 till the expiry of 48 hours after the declaration of Unaudited Financial results for the quarter and half year ended September 30, 2026 and accordingly, the trading window shall remain closed till Saturday, November 07, 2026 and shall re-open thereafter, i.e. on Glenmark Pharmaceuticals Limited Glenmark House, B. D. Sawant Marg, Andheri (East), Mumbai 400 099, India T: +91 22 4018 9999 F: +91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com Sunday, November 08, 2026. This is for your information, and you are requested to bring this to the notice of your constituents and take the above information on your record. Thanking You. Yours faithfully, For Glenmark Pharmaceuticals Limited Rashmi Khandelwal Company Secretary & Compliance Officer ACS - 28839 Glenmark Pharmaceuticals Limited Glenmark House, B. D. Sawant Marg, Andheri (East), Mumbai 400 099, India T: +91 22 4018 9999 F: +91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com